TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
- Journal
- Nature Communications
In The Last Decade
doi.org/10.1038/ncomms5309 →Countries where authors are citing TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
This map shows the geographic impact of TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease more than expected).
Fields of papers citing TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
This network shows the impact of TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
About TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
This paper, published in 2014, received 454 indexed citations . Written by Yang‐Lin Liu, Helen L. Reeves, Alastair D. Burt, Dina Tiniakos, Stuart McPherson, Julian Leathart, Michael Allison, Graeme Alexander, A.-C. Piguet and Rodolphe Anty covering the research area of Epidemiology, Cell Biology and Endocrinology, Diabetes and Metabolism. It is primarily cited by scholars working on Epidemiology (428 citations), Endocrinology, Diabetes and Metabolism (211 citations) and Hepatology (163 citations). Published in Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/ncomms5309.